Abstract
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide.
Kalorama' s Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for treatments for these two important diseases in the autoimmune disorder category: rheumatoid arthritis and lupus. As part of its thorough, ground up research-- the product of interviews with market experts conducted by an experienced pharmaceutical market analyst, this report includes:
- Market Size and Forecast for NSAIDs and Biologic Treatments
- New Products in Development
- Important Issues and Trends
- Company Profiles
- Market Share
- Regional Revenues Breakout
Product Managers, marketing managers, business development executives and investment professionals are among those who will find this report to be a useful resource.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- History of the Market
- Immune System
- Autoimmunity
- Genetic Factors
- Environmental Factors
- Gene Research
- Distribution
- Technology
- Demographics
CHAPTER THREE: MARKETS FOR RHEUMATOID ARTHRITIS
- Overview
- Description of Rheumatoid Arthritis
- Diagnosis
- Treatment Guidelines
- Economic Impact of Disease
- Trends in Insurance and Reimbursement
- Description of products
- Non-steroid Anti-inflammatory Drugs
- Biologic Treatments
- Disease Modifying Anti-rheumatic Drugs (DMARDs)
- Immunosuppressant and Other Biologic Drugs
- New Developments
- Market Overview
- Market by Product Type
- Market by Geographical Region
- Competitive Analysis
- Corporate Profiles
- Abbott Laboratories
- Amgen, Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Centocor, Inc.
- Genentech, Inc.
- Merck & Company, Inc.
- Novartis International AG
- Pfizer, Inc.
- Schering-Plough Corporation
- Wyeth
CHAPTER FOUR: MARKETS FOR LUPUS ERYTHEMATOSUS
- Overview
- Description of Lupus Erythematosus
- Diagnosis
- Risk Factors
- Treatment Guidelines
- Economic Impact of Disease
- Trends in Insurance and Reimbursement
- Description of products
- New Developments
- Market Overview
- Market by Product Type
- Market by Geographical Region
- Competitive Analysis
- Corporate Profiles
- Aspreva Pharmaceuticals Corporation
- Bristol-Myers Squibb
- Genelabs Technologies, Inc.
- Genentech, Inc.
- GlaxoSmithKline plc
- Human Genome Sciences
- La Jolla Pharmaceutical Company
- Roche
- UCB S.A.
CHAPTER FIVE: TOTAL MARKET SIZE AND FORECAST
- Overview
- Total Market Size and Forecast
- Markets by Segments
- Leading Competitors
CHAPTER SIX: LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011
- Figure 1-1: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011
CHAPTER TWO: INTRODUCTION
- Table 2-1: World Population by Selected Geographical Region, 2006-2050
- Figure 2-1: World Population by Selected Geographical Region, 2006-2050
- Table 2-2: Estimated World Population by Age and Geographical Region, 2006
- Table 2-2: Estimated World Population by Age and Geographical Region, 2006
CHAPTER THREE: RHEUMATOID ARTHRITIS MARKETS
- Table 3-1: World Prevalence of Rheumatoid Arthritis by Region 25
- Figure 3-1: World Prevalence of Rheumatoid Arthritis, Percent by Region
- Table 3-2: Select Marketed Non-steroidal Anti-inflammatory Drugs
- Table 3-3: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
- Table 3-4: Selected Prescription Immunosuppressant and Other Biologic Drugs
- Table 3-5: New Developments in Rheumatoid Arthritis
- Figure 3-2: Number of New Developments for Rheumatoid Arthritis by Development Phase
- Table 3-6: The World Market for Prescription Rheumatoid Arthritis Treatments, 2004-2011
- Figure 3-3: The World Market for Prescription Rheumatoid Arthritis Treatments, 2004-2011
- Table 3-7: The World Market for Prescription Rheumatoid Arthritis Treatments, by Product Type, 2004-2011
- Figure 3-4:The World Market for Prescription Rheumatoid Arthritis Treatments, by Product Type, 2004-2011
- Figure 3-5: The World Market for Prescription Rheumatoid Arthritis Treatments, by Product Type and Percent Distribution, 2004-2011
- Figure 3-6: The World Market for Prescription Rheumatoid Arthritis Treatments, by Percent and Product Type, 2006
- Figure 3-7: The World Market for Prescription Rheumatoid Arthritis Treatments, by Percent and Product Type, 2011
- Table 3-8: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2006
- Figure 3-8: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2006
- Table 3-9: Leading Suppliers' Shares of the World Market for Prescription Rheumatoid Arthritis Treatments, 2006
- Figure 3-9: Leading Suppliers' Shares of the World Market for Prescription Rheumatoid Arthritis Treatments, 2006
CHAPTER FOUR: LUPUS TREATMENT MARKETS
- Table 4-1: World Prevalence of Lupus by Region
- Figure 4-1: World Prevalence of Lupus, Percent by Region
- Table 4-2: Select Marketed Non-steroidal Anti-inflammatory Drugs
- Table 4-3: Selected Corticosteroids, Immunosuppressives and DMARDs
- Table 4-4: New Developments in Lupus Erythrematosus
- Figure 4-2: Number of New Developments for Lupus Erythrematosus by Development Phase Table 4-5: The World Market for Prescription Lupus Treatments, 2004-2011
- Figure 4-3: The World Market for Prescription Lupus Treatments, 2004-2011
- Table 4-6: The World Market for Prescription Lupus Treatments, by Product Type, 2004-2011
- Figure 4-4: The World Market for Prescription Lupus Treatments, by Product Type, 2004-2011
- Figure 4-5: The World Market for Prescription Lupus Treatments, by Product Type and Percent Distribution, 2004-2011
- Figure 4-6: The World Market for Prescription Lupus Treatments, by Percent and Product Type, 2006
- Figure 4-7: The World Market for Prescription Lupus Treatments, by Percent and Product Type, 2011
- Table 4-7: The World Market for Prescription Lupus Treatments, by Geographic Region, 2006
- Figure 4-8: The World Market for Prescription Lupus Treatments, by Geographic Region, 2006
- Table 4-8: Estimated Leading Suppliers' Shares of the World Market for Prescription Lupus Treatments, 2011
- Figure 4-9: Estimated Leading Suppliers' Shares of the World Market for Prescription Lupus Treatments, 2011
CHAPTER FIVE: WORLD MARKET SUMMARY
- Table 5-1: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011
- Figure 5-1: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011
- Table 5-2: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Product Type, 2004-2011
- Figure 5-3: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Product Type, 2004-2011
- Figure 5-4: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Product Type and Percent Distribution, 2004-2011
- Figure 5-5: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Percent and Product Type, 2006
- Figure 5-6: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Percent and Product Type, 2011
